RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE)…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
IN THE NEWS
06/09/2025
SparingVision appoints Dr. Kali Stasi as Chief Medical Officer
- Experienced global leader in ophthalmology and gene therapy…
04/08/2025
Opus Genetics Announces One-Month Clinical Data from Pediatric Pati…
First pediatric patient shows encouraging early safety profi…
04/02/2025
Atsena Therapeutics Announces Oversubscribed $150 Million Series C…
Financing led by new investor Bain Capital with participatio…
02/18/2025
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
First patient dosed in the pediatric cohort of the Phase 1/2…
02/18/2025
Perceive Pharma Attracts $15M Series A Financing to Advance Ophthal…
Funding to fuel company's progress in driving lead glaucoma …
11/13/2024
Nippon Shinyaku and Atsena Therapeutics Enter into an Exclusive Str…
Nippon Shinyaku and Atsena Therapeutics Enter into an Exclus…
10/25/2024
The RD Fund Announces Ocuphire Pharma’s Acquisition of Opus Genetic…
The resulting company will operate under the name Opus Genet…
10/24/2024
SparingVision Presents Updates on PRODYGY Trial and PHENOROD2 Study…
First oral presentation on PRODYGY at a major cell and gene …
10/22/2024
Ocuphire Pharma Announces Acquisition of Opus Genetics
Acquisition creates a leading, clinical-stage company focuse…
09/23/2024
SparingVision Reports Progress on SPVN06 at Major Ophthalmology Con…
SPVN06 demonstrates continued favorable safety profile at 12…